Please login to the form below
Biosimilars in 2018: EU doctors’ perceptions of RA drug market
Published in pharmaphorum October 2015 by Laurent Chanroux
Physicians in Europe's Big 5 think current market leaders will continue to lead, with biosimilars making the greatest inroads in the field up to 2018, if clearer guidance on efficacy and safety is provided.
A panel of around 200 physicians treating RA across Europe (France, Germany, Italy, Spain and the UK) were asked how they currently treat their patients and what they expect to be doing in 2018. The findings suggest that the market leaders can breathe easy, for the moment at least.
Read the full article here:
www.researchpartnership.com/news/2015/10/article-biosimilars-in-2018-ra-perceptions/
A panel of around 200 physicians treating RA across Europe (France, Germany, Italy, Spain and the UK) were asked how they currently treat their patients and what they expect to be doing in 2018. The findings suggest that the market leaders can breathe easy, for the moment at least.
Read the full article here:
www.researchpartnership.com/news/2015/10/article-biosimilars-in-2018-ra-perceptions/
Company Details
Research Partnership
+44 (0)20 8069 5000
Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom
Latest content on this profile
- Video
- Virtual Conference Live
Research Partnership
- Report
- Digital Health Tools - Physician Trends
Research Partnership
- Live webinar:
- Oncology landscape: How innovative market research methods can navigate you to success
Research Partnership
- Article:
- The disparity of patient experiences with Crohn’s Disease in Europe and Japan
Research Partnership
- Research Partnership’s MedTech Division appoints two Directors
- Chris Carles has joined as a Director in our Philadelphia office and Andrew Way as a Research Director in our UK office.
Research Partnership
- Webcast: Influencing HCP behaviours – Is now the perfect opportunity?
- Putting behavioural science at the forefront of market research
Research Partnership
